News
The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...
Sarepta ( SRPT) will begin shipping its top-selling muscular dystrophy therapy, Elevidys, after the U.S. Food and Drug ...
The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients ...
Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug ...
FDA recommends lifting the hold on Sarepta's gene therapy Elevidys for ambulatory patients after investigation; ...
A boy who was carried home from a birthday party suffering with what his parents thought was cramp has since been diagnosed ...
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
Sarepta Therapeutics (NASDAQ:SRPT) said late Monday it will pause all shipments of its Duchenne muscular dystrophy gene ...
The patient with Duchenne muscular dystrophy, who died in Brazil, was treated with Elevidys but was not a participant in a ...
A Dardenne Prairie family has turned heartbreak into hope, raising over $100,000 for muscular dystrophy research after losing ...
Capricor Therapeutics Reports Positive Four-Year Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2025 Annual Conference June 20, 2025 — 09:31 am EDT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results